Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL).
Tatsuro Jo
Honoraria - Kyowa Hakko Kirin
Takashi Ishida
Consultant or Advisory Role - Kyowa Hakko Kirin (U)
Honoraria - Kyowa Hakko Kirin
Research Funding - Kyowa Hakko Kirin
Shigeki Takemoto
No relevant relationships to disclose
Hitoshi Suzushima
No relevant relationships to disclose
KImiharu Uozumi
Consultant or Advisory Role - Kyowa Hakko Kirin (U)
Kazuhito Yamamoto
Consultant or Advisory Role - Kyowa Hakko Kirin (U)
Honoraria - Kyowa Hakko Kirin
Naokuni Uike
Consultant or Advisory Role - Kyowa Hakko Kirin (U)
Yoshio Saburi
No relevant relationships to disclose
Kisato Nosaka
No relevant relationships to disclose
Atae Utsunomiya
Consultant or Advisory Role - Kyowa Hakko Kirin (U)
Honoraria - Kyowa Hakko Kirin
Kensei Tobinai
Consultant or Advisory Role - Kyowa Hakko Kirin
Honoraria - Kyowa Hakko Kirin
Research Funding - Kyowa Hakko Kirin
Hiroshi Fujiwara
No relevant relationships to disclose
Kenji Ishitsuka
No relevant relationships to disclose
Shinichiro Yoshida
No relevant relationships to disclose
Naoya Taira
No relevant relationships to disclose
Yukiyoshi Moriuchi
No relevant relationships to disclose
Kazunori Imada
No relevant relationships to disclose
Toshihiro Miyamoto
No relevant relationships to disclose
Masao Tomonaga
Consultant or Advisory Role - Kyowa Hakko Kirin
Ryuzo Ueda
Other Remuneration - Kyowa Hakko Kirin